Michael Barbella, Managing Editor02.26.24
Durin Technologies Inc. has received $3.5 million in funding, led by Breakthrough Diagnostics LLC.
The funding will accelerate Durin’s next key stages of anticipated growth, involving commercializing its diagnostic tests for Alzheimer’s and Parkinson’s diseases and developing its next generation of diagnostic tests that detect other diseases and disorders at their earliest stages.
“With this latest funding, we are poised to bring our tests into the market and move closer to satisfying the demands of physicians, patients and their loved ones with fast, easy-to-understand and reliable diagnosis of life altering diseases,” Durin Technologies CEO Mert Sahin, Ph.D., said.
Durin Technologies develops non-invasive, easy access diagnostic tests for the most prevalent and devastating neurodegenerative disorders, including Alzheimer's and Parkinson's diseases. Its rapid-result, high-accuracy Duritect diagnostic tests make early detection and monitoring of disease progression possible—in a decade or more prior to symptoms in some cases. Durin’s first two tests—for Alzheimer's and Parkinson’s—are expected to be released to market this year, followed by tests for other diseases. The company’s science creates a scalable platform for diagnostic tests that will extend beyond the multi-billion-dollar neurodegenerative diagnostics market into the much larger, broader disease diagnostic market.
The funding will accelerate Durin’s next key stages of anticipated growth, involving commercializing its diagnostic tests for Alzheimer’s and Parkinson’s diseases and developing its next generation of diagnostic tests that detect other diseases and disorders at their earliest stages.
“With this latest funding, we are poised to bring our tests into the market and move closer to satisfying the demands of physicians, patients and their loved ones with fast, easy-to-understand and reliable diagnosis of life altering diseases,” Durin Technologies CEO Mert Sahin, Ph.D., said.
Durin Technologies develops non-invasive, easy access diagnostic tests for the most prevalent and devastating neurodegenerative disorders, including Alzheimer's and Parkinson's diseases. Its rapid-result, high-accuracy Duritect diagnostic tests make early detection and monitoring of disease progression possible—in a decade or more prior to symptoms in some cases. Durin’s first two tests—for Alzheimer's and Parkinson’s—are expected to be released to market this year, followed by tests for other diseases. The company’s science creates a scalable platform for diagnostic tests that will extend beyond the multi-billion-dollar neurodegenerative diagnostics market into the much larger, broader disease diagnostic market.